The Zio found AFib in 5% of those who wore it, compared with 3.3% in the group that didn’t get the heart monitor. Most of ...
The Japanese Pharmaceutical and Medical Device Agency (PMDA) has approved iRhythm Technologies’ Zio ECG monitoring system, an ...
The company also entered into an exclusive licensing agreement with BioIntelliSense, Inc., enhancing its ambulatory cardiac monitoring offerings. iRhythm's Zio ECG monitoring system received ...
which is used for the provision of our mobile cardiac telemetry (MCT) services. The Zio AT system consists of: the Zio AT patch, an ECG monitor that continuously records ECG data for up to 14 days ...
Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients ...
SAN FRANCISCO - iRhythm Technologies, Inc. (NASDAQ:IRTC), a company specializing in digital healthcare solutions, announced today that it has received clearance from the U.S. Food and Drug ...
which is used for the provision of our mobile cardiac telemetry (MCT) services. The Zio AT system consists of: the Zio AT patch, an ECG monitor that continuously records ECG data for up to 14 days ...
The Zio AT device is intended to capture and transmit symptomatic and asymptomatic cardiac events and record continuous electrocardiogram (ECG) data for long-term monitoring. It is indicated for ...
Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients FDA ...